ISOPP CAPhO 2025 Symposium: Sponsored Breakfast Symposium Merck Canada and AstraZeneca Canada - PARP Inhibitor Pan-Tumour Clinical Resource: Supporting Oncology Pharmacists in Managing Breast, Prostate, Ovarian, and Pancreatic Cancers

Following the initial use of PARP inhibitors in ovarian cancer, their role has expanded to include treatment of several early and later stage cancers including breast, prostate and pancreatic cancer. This case-based session will bring together practitioners with experience in managing patients receiving PARP inhibitors to discuss practical strategies for optimizing the benefits of treatment through proactive toxicity management. The presenters will review the CANO-endorsed PARP Inhibitor Clinical Resource and application of this tool in routine practice.

Learning Objectives

• Explain the role of PARP inhibitor therapy in the treatment of breast, prostate, and ovarian cancers
• Understand the similarities and differences in the clinical management of patients with different solid tumours who are receiving PARP inhibitor therapy
• Implement proactive and reactive toxicity management strategies from the CANO-endorsed PARP Inhibitor Clinical Resource to optimize tolerability and clinical benefit from PARP inhibitor therapy